Dipeptidyl peptidase

Results: 124



#Item
81*JANUVIA™ is the proposed trademark for MK-431 (sitagliptin phosphate)

*JANUVIA™ is the proposed trademark for MK-431 (sitagliptin phosphate)

Add to Reading List

Source URL: www.merck.ca

Language: English - Date: 2014-10-08 00:16:31
82CANADIAN DIABETES ASSOCIATION 2013 CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION AND MANAGEMENT OF DIABETES IN CANADA DUALITY OF INTEREST DISCLOSURES EXECUTIVE, STEERING & EXPERT COMMITTEES

CANADIAN DIABETES ASSOCIATION 2013 CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION AND MANAGEMENT OF DIABETES IN CANADA DUALITY OF INTEREST DISCLOSURES EXECUTIVE, STEERING & EXPERT COMMITTEES

Add to Reading List

Source URL: guidelines.diabetes.ca

Language: English - Date: 2013-04-24 07:17:09
83Microsoft Word - Dipeptidyl Peptidase-4 _DPP-4_ PDST Summary-Final-V3[removed]doc

Microsoft Word - Dipeptidyl Peptidase-4 _DPP-4_ PDST Summary-Final-V3[removed]doc

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2013-10-03 14:58:53
84 Formulary Alternatives for Non-formulary Medications Cost Share Changes Effective July 11, 2012 Non-Formulary (Tier 3) Medications Dipeptidyl Peptidase Inhibitors (DPP4s) Cost share = $25 †

Formulary Alternatives for Non-formulary Medications Cost Share Changes Effective July 11, 2012 Non-Formulary (Tier 3) Medications Dipeptidyl Peptidase Inhibitors (DPP4s) Cost share = $25 †

Add to Reading List

Source URL: www.express-scripts.com

Language: English - Date: 2012-07-12 14:34:08
85Report on the Deliberation Results August 25, 2009 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare

Report on the Deliberation Results August 25, 2009 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare

Add to Reading List

Source URL: www.pmda.go.jp

Language: English - Date: 2014-03-10 21:30:33
86Estimating the cardiovascular benefits of DPP-4 inhibitors: a simulated study PCV15 C. Andy Schuetz1, Tina Yeung1, Matthias Blüher2, Siew Hwa Ong3

Estimating the cardiovascular benefits of DPP-4 inhibitors: a simulated study PCV15 C. Andy Schuetz1, Tina Yeung1, Matthias Blüher2, Siew Hwa Ong3

Add to Reading List

Source URL: archimedesmodel.com

Language: English - Date: 2013-11-21 17:58:56
87COMMONWEALTH OF KENTUCKY CABINET FOR HEALTH AND FAMILY SERVICES DEPARTMENT FOR MEDICAID SERVICES PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING Capitol Annex -Room[removed]Capital Avenue Frankfort, Kentucky 40601

COMMONWEALTH OF KENTUCKY CABINET FOR HEALTH AND FAMILY SERVICES DEPARTMENT FOR MEDICAID SERVICES PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING Capitol Annex -Room[removed]Capital Avenue Frankfort, Kentucky 40601

Add to Reading List

Source URL: www.chfs.ky.gov

Language: English - Date: 2014-09-05 04:20:09
88What’s “hot” about thermogenic agents

What’s “hot” about thermogenic agents

Add to Reading List

Source URL: dpic.org

Language: English - Date: 2013-06-09 23:17:15
89Saskatchewan Ministry of Health Drug Plan and Extended Benefits Branch January 1, 2012 Bulletin #131 ISSN 1923-077X

Saskatchewan Ministry of Health Drug Plan and Extended Benefits Branch January 1, 2012 Bulletin #131 ISSN 1923-077X

Add to Reading List

Source URL: formulary.drugplan.health.gov.sk.ca

Language: English - Date: 2014-06-26 15:57:49
90HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) Tablets Initia

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) Tablets Initia

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-03-27 13:52:29